Results 111 to 120 of about 16,400 (167)

Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era. [PDF]

Sci Rep
Yamasaki S, Shimazu Y, Misaki Y, Onizuka M, Sawa M, Kanda Y, Fukuda T, Hashimoto C, Yoshimitsu M, Kanda J, Atsuta Y, Kako S.   +11 more
europepmc   +1 more source

Neurotensin Receptor 1 Regulates HER4 Tyrosine Phosphorylation in Lung Cancer Cells. [PDF]

Biology (Basel)
Moody TW, Ramos-Alvarez I, Jensen RT.
europepmc   +1 more source

Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China. [PDF]

Health Econ Rev
Liu Y, Li W, Wei X, Guan H, Han S.
europepmc   +1 more source

Real-World Treatment Patterns and Safety Outcomes of Targeted Therapies in a Single-Center Chronic Lymphocytic Leukemia Cohort. [PDF]

Medicina (Kaunas)
Jeral Evinç S, Eyüpler Akmercan Ç, Ercan T, Arıkan F, Mengüç MU, Toptaş T, Atagündüz I, Tuğlular T, Yılmaz AF.   +8 more
europepmc   +1 more source

Ibrutinib-Related Stellar Hematomas of the Palms. [PDF]

Dermatol Pract Concept
Sanz PL, Salvat CG, Faure IG, Baldó JÀ, Masoliver AA.   +4 more
europepmc   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. [PDF]

Hemasphere
Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N.   +13 more
europepmc   +1 more source

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study. [PDF]

Cancers (Basel)
Molica S, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Palma M, Arienti D, Mauro FR.   +37 more
europepmc   +1 more source

Evaluation of Real-world treatment patterns in Japanese patients with cGVHD: A retrospective claims database study. [PDF]

Int J Hematol
Kanda J, Wattanakamolkul K, Muromine H, Shiga K.   +3 more
europepmc   +1 more source

Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. [PDF]

Blood Adv
Castonguay M, Anderson MA, Thompson P, Seymour JF.   +3 more
europepmc   +1 more source

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report. [PDF]

Leuk Res Rep
Chiang TL, Frater J, Cashen A.
europepmc   +1 more source